View Exam | PowerPak

1. In severe cases of COVID-19, a dysregulated immune response may result in hyperinflammation. Consequences can include coagulation dysfunction, thrombosis, and organ damage to the lungs and/or other organs. Which of the following is a hallmark of the hyperinflammatory response?

A. Increased killer T-cell activation B. Reduced activation of macrophages C. Excessive cytokine production D. Excessive antibody production E. Unsure

2. The active components of available monoclonal antibody (mAb) treatments target the regions of the SARS-CoV-2 spike (S) protein. Which of the following accurately describes the binding of those mAbs?

A. Sotrovimab binds to an epitope outside of the receptor binding domain (RBD) of the S1 subunit B. Casirivimab and imdevimab bind to conserved epitopes of the RBD of the S1 subunit C. Bamlanivimab and etesevimab bind to conserved epitopes of the RBD of the S1 subunit D. Sotrovimab binds to a conserved epitope of the RBD of the S1 subunit E. Unsure

3. The indications specified in the emergency use authorizations (EUAs) for the COVID-19 mAb treatments limit their use to nonhospitalized patients who are at high risk of progressing to severe COVID-19 disease. Which of the following is a disease state or condition that identifies a patient as high risk?

A. Immunocompromised state B. Age < 65 years C. Previous infection by SARS-CoV-2 D. Gout E. Unsure

4. Which of the following best describes the mechanism of action of the COVID-19 mAbs?

A. Sotrovimab binds to the S1 RBD to prevent binding of SARS-CoV-2 to ACE2 receptor B. Sotrovimab binds to the S2 RBD to prevent SARS-CoV-2 fusion with the cell C. Bamlanivimab and etesevimab bind to the S1 RBD to prevent binding of SARS-CoV-2 to ACE2 receptor D. Casirivimab and imdevimab bind to the S1 RBD to prevent SARS-CoV-2 fusion with the cell E. Unsure

5. In the clinical trials supporting the efficacy of COVID-19 mAb therapeutics, the adverse event profiles of the drugs were generally mild comparable to placebo. Protein-based drugs such as mAbs, however, are susceptible to which of the following adverse events?

A. Increased risk of nosocomial infections B. Hypersensitivity and infusion reactions C. Toxicity to breast-fed infants D. Fetal toxicity when administered to pregnant persons E. Unsure

6. Per the COVID-19 Treatment Guidelines Panel of the NIH (as of February 1, 2022), which of the following best describes the recommended dosing regimen for sotrovimab for high-risk, nonhospitalized patients with mild-to-moderate COVID-19?

A. Single IV infusion of 500 mg, administered as soon as possible (within 10 days of symptom onset) in patients ≥ 12 years old and weighing ≥ 40 kg B. Single IV infusion of 500 mg, administered as soon as possible (within 10 days of symptom onset) in patients ≥ 18 years old and weighing ≥ 40 kg C. Single IV infusion of 1000 mg, administered as soon as possible (within 10 days of symptom onset) in patients ≥ 12 years old and weighing ≥ 40 kg D. IV infusion of 500 mg once per day for 2 days, administered as soon as possible (within 10 days of symptom onset) in patients ≥ 12 years old and weighing ≥ 40 kg E. Unsure

7. Throughout the COVID-19 pandemic, mutations to SARS-CoV-2 have created a number of variants, some of which become the dominant form of the virus spreading infection. At time of publication, the omicron was the dominant variant in the United States. Which of the following best describes the relationship between omicron variant and COVID-19 mAb therapeutics?

A. Omicron mutations have not affected the efficacies of mAb therapeutics B. Only sotrovimab has retained efficacy against omicron C. Only bamlanivimab and etesevimab have retained efficacy against omicron D. Only casirivimab and imdevimab have retained efficacy against omicron E. Unsure

8. There are limited data on the use of bamlanivimab/etesevimab, casirivimab/imdevimab, and sotrovimab in women who are breast feeding. Therefore, the current recommendation is to use these drugs with caution in that patient population. Which of the following properties of the mAbs make them unlikely to be excreted in breast milk?

A. Limited binding of mAbs to plasma proteins B. Intravenous route of administration C. Net negative charge of the molecules D. High molecular weight E. Unsure

9. Use this CASE to answer questions 9 and 10.
SC is a 55-year-old male with a BMI = 31.1. SC is a former 1 pack/d smoker (stopped 2 years ago) with a history of type 2 diabetes, renal insufficiency, and asthma.
Current medications:
COVID-19 Vaccination: 1 dose of COVID-19 mRNA vaccine, next dose due in 3 weeks Use the case information to answer questions 9 and 10

Per the CDC, which of the following DOES NOT contribute to SC’s risk for developing severe illness if he contracts COVID-19?

A. Body weight/BMI B. Age C. Asthma D. Type 2 diabetes E. Unsure

10. SC tests positive for COVID-19 via a rapid, at-home test and starts to experience symptoms of fever and shortness of breath. SC's physician prescribes a course of sotrovimab. After 15 min of infusion, SC exhibits signs of hypersensitivity. Which of the following would be the best course of action to take?

A. Immediately stop infusion and administer tixagevimab/cilgavimab B. Pause infusion until symptoms dissipate; restart infusion within an hour C. Immediately stop infusion and initiate appropriate medications and/or supportive care D. Pause infusion until symptoms improve; restart infusion within 30 min E. Unsure

Evaluation Questions

11. How confident are you in your treatment choice for SC in the question above?

A. Not at all confident B. Somewhat confident C. Confident D. Highly confident

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In severe cases of COVID-19, a dysregulated immune response may result in hyperinflammation. Consequences can include coagulation dysfunction, thrombosis, and organ damage to the lungs and/or other organs. Which of the following is a hallmark of the hyperinflammatory response?

2. The active components of available monoclonal antibody (mAb) treatments target the regions of the SARS-CoV-2 spike (S) protein. Which of the following accurately describes the binding of those mAbs?

4. Which of the following best describes the mechanism of action of the COVID-19 mAbs?

5. In the clinical trials supporting the efficacy of COVID-19 mAb therapeutics, the adverse event profiles of the drugs were generally mild comparable to placebo. Protein-based drugs such as mAbs, however, are susceptible to which of the following adverse events?

6. Per the COVID-19 Treatment Guidelines Panel of the NIH (as of February 1, 2022), which of the following best describes the recommended dosing regimen for sotrovimab for high-risk, nonhospitalized patients with mild-to-moderate COVID-19?

Evaluation Questions

11. How confident are you in your treatment choice for SC in the question above?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. In severe cases of COVID-19, a dysregulated immune response may result in hyperinflammation. Consequences can include coagulation dysfunction, thrombosis, and organ damage to the lungs and/or other organs. Which of the following is a hallmark of the hyperinflammatory response?

2. The active components of available monoclonal antibody (mAb) treatments target the regions of the SARS-CoV-2 spike (S) protein. Which of the following accurately describes the binding of those mAbs?

4. Which of the following best describes the mechanism of action of the COVID-19 mAbs?

5. In the clinical trials supporting the efficacy of COVID-19 mAb therapeutics, the adverse event profiles of the drugs were generally mild comparable to placebo. Protein-based drugs such as mAbs, however, are susceptible to which of the following adverse events?

6. Per the COVID-19 Treatment Guidelines Panel of the NIH (as of February 1, 2022), which of the following best describes the recommended dosing regimen for sotrovimab for high-risk, nonhospitalized patients with mild-to-moderate COVID-19?

Evaluation Questions

11. How confident are you in your treatment choice for SC in the question above?

« Return to Activity

Customers who Purchased
this Activity also Purchased